{"transactions":[{"id":730040,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2026-06-22T20:30:09.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":51700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027."}],"balance_after":51700,"derivative":{"exercise_price":2.55,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":51700},"source":{"system":"sec-edgar","filing":"0001650664-26-000070","document":"wk-form4_1782160207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000165066426000070/wk-form4_1782160207.xml","form_type":"4"}},{"id":895836,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-02-18T22:04:58.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":9057,"price":1.89,"value":17117.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":1074934,"source":{"system":"sec-edgar","filing":"0001470831-26-000177","document":"wk-form4_1771452294.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000147083126000177/wk-form4_1771452294.xml","form_type":"4"}},{"id":895835,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-02-18T22:04:58.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025."}],"balance_after":1083991,"source":{"system":"sec-edgar","filing":"0001470831-26-000177","document":"wk-form4_1771452294.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000147083126000177/wk-form4_1771452294.xml","form_type":"4"}},{"id":895834,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-02-18T22:04:58.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":39154,"price":1.89,"value":74001.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":1083991,"source":{"system":"sec-edgar","filing":"0001470831-26-000177","document":"wk-form4_1771452294.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000147083126000177/wk-form4_1771452294.xml","form_type":"4"}},{"id":895833,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-02-18T22:04:58.000Z","date":"2026-02-14","kind":"exercise","planned":false,"acquired":true,"shares":81725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025."}],"balance_after":1123145,"source":{"system":"sec-edgar","filing":"0001470831-26-000177","document":"wk-form4_1771452294.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000147083126000177/wk-form4_1771452294.xml","form_type":"4"}},{"id":895832,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-02-18T22:04:58.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones."}],"balance_after":1123145,"source":{"system":"sec-edgar","filing":"0001470831-26-000177","document":"wk-form4_1771452294.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000147083126000177/wk-form4_1771452294.xml","form_type":"4"}},{"id":1115989,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2025-06-10T20:18:00.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026."}],"balance_after":37500,"derivative":{"exercise_price":1.91,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001650664-25-000099","document":"wk-form4_1749586673.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000165066425000099/wk-form4_1749586673.xml","form_type":"4"}},{"id":1263278,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:55:35.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":335300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025."}],"balance_after":335300,"derivative":{"exercise_price":3.18,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":335300},"source":{"system":"sec-edgar","filing":"0001662579-25-000021","document":"wk-form4_1739915729.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257925000021/wk-form4_1739915729.xml","form_type":"4"}},{"id":1263277,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-18T21:55:35.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":9370,"price":3.18,"value":29796.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":423145,"source":{"system":"sec-edgar","filing":"0001662579-25-000021","document":"wk-form4_1739915729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257925000021/wk-form4_1739915729.xml","form_type":"4"}},{"id":1263276,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-18T21:55:35.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":12847,"price":3.18,"value":40853.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":432515,"source":{"system":"sec-edgar","filing":"0001662579-25-000021","document":"wk-form4_1739915729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257925000021/wk-form4_1739915729.xml","form_type":"4"}},{"id":1263275,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-18T21:55:35.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":223500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026."}],"balance_after":445362,"source":{"system":"sec-edgar","filing":"0001662579-25-000021","document":"wk-form4_1739915729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257925000021/wk-form4_1739915729.xml","form_type":"4"}},{"id":1368319,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2024-11-12T21:17:00.000Z","date":"2024-11-07","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":35000,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001662579-24-000100","document":"wk-form4_1731446213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000100/wk-form4_1731446213.xml","form_type":"4"}},{"id":1368318,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-11-12T21:17:00.000Z","date":"2024-11-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":5550,"price":6.04,"value":33522.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":221862,"source":{"system":"sec-edgar","filing":"0001662579-24-000100","document":"wk-form4_1731446213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000100/wk-form4_1731446213.xml","form_type":"4"}},{"id":1368317,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-11-12T21:17:00.000Z","date":"2024-11-07","kind":"exercise","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":227412,"source":{"system":"sec-edgar","filing":"0001662579-24-000100","document":"wk-form4_1731446213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000100/wk-form4_1731446213.xml","form_type":"4"}},{"id":1404724,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2024-09-17T21:12:47.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":47500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001662579-24-000084","document":"wk-form4_1726607560.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000084/wk-form4_1726607560.xml","form_type":"4"}},{"id":1404723,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-17T21:12:47.000Z","date":"2024-09-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":3329,"price":6.36,"value":21172.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":214912,"source":{"system":"sec-edgar","filing":"0001662579-24-000084","document":"wk-form4_1726607560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000084/wk-form4_1726607560.xml","form_type":"4"}},{"id":1404722,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-17T21:12:47.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":218241,"source":{"system":"sec-edgar","filing":"0001662579-24-000084","document":"wk-form4_1726607560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000084/wk-form4_1726607560.xml","form_type":"4"}},{"id":1494805,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2024-06-03T21:11:14.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025."}],"balance_after":25000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001650664-24-000068","document":"wk-form4_1717449062.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000165066424000068/wk-form4_1717449062.xml","form_type":"4"}},{"id":1640606,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-02-15T23:18:19.000Z","date":"2024-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":6560,"price":7.9,"value":51824.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":210741,"source":{"system":"sec-edgar","filing":"0001662579-24-000022","document":"wk-form4_1708039090.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000022/wk-form4_1708039090.xml","form_type":"4"}},{"id":1640604,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:08:51.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":465500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024."}],"balance_after":465500,"derivative":{"exercise_price":7.31,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":465500},"source":{"system":"sec-edgar","filing":"0001662579-24-000020","document":"wk-form4_1708034921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000020/wk-form4_1708034921.xml","form_type":"4"}},{"id":1640603,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-02-15T22:08:51.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":103400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025."}],"balance_after":217301,"source":{"system":"sec-edgar","filing":"0001662579-24-000020","document":"wk-form4_1708034921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257924000020/wk-form4_1708034921.xml","form_type":"4"}},{"id":1777013,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-19T23:24:44.000Z","date":"2023-09-18","kind":"grant","planned":false,"acquired":true,"shares":489600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date."}],"balance_after":489600,"derivative":{"exercise_price":2.15,"expiration_date":"2033-09-17","underlying":"Common Stock","underlying_shares":489600},"source":{"system":"sec-edgar","filing":"0001662579-23-000102","document":"wk-form4_1695165874.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000102/wk-form4_1695165874.xml","form_type":"4"}},{"id":1791740,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2023-08-31T20:13:51.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":55000,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001662579-23-000086","document":"wk-form4_1693512793.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000086/wk-form4_1693512793.xml","form_type":"4"}},{"id":1791739,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-08-31T20:13:51.000Z","date":"2023-08-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2205,"price":2.93,"value":6460.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":113901,"source":{"system":"sec-edgar","filing":"0001662579-23-000086","document":"wk-form4_1693512793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000086/wk-form4_1693512793.xml","form_type":"4"}},{"id":1791738,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-08-31T20:13:51.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":116106,"source":{"system":"sec-edgar","filing":"0001662579-23-000086","document":"wk-form4_1693512793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000086/wk-form4_1693512793.xml","form_type":"4"}},{"id":1866148,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T20:30:27.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024."}],"balance_after":25000,"derivative":{"exercise_price":9.55,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009231","document":"form4-06052023_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000141588923009231/form4-06052023_040604.xml","form_type":"4"}},{"id":2013190,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T21:44:26.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":367200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 15, 2023."}],"balance_after":367200,"derivative":{"exercise_price":5.77,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":367200},"source":{"system":"sec-edgar","filing":"0001662579-23-000034","document":"wf-form4_167649743141884.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000034/wf-form4_167649743141884.xml","form_type":"4"}},{"id":2013189,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-02-15T21:44:26.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":81600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 15, 2024."}],"balance_after":108606,"source":{"system":"sec-edgar","filing":"0001662579-23-000034","document":"wf-form4_167649743141884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000034/wf-form4_167649743141884.xml","form_type":"4"}},{"id":2038256,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2023-02-01T21:09:52.000Z","date":"2023-01-30","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":62500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001662579-23-000021","document":"wf-form4_167528577737212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000021/wf-form4_167528577737212.xml","form_type":"4"}},{"id":2038255,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-02-01T21:09:52.000Z","date":"2023-01-30","kind":"tax_withholding","acquired":false,"shares":4319,"price":7.78,"value":33601.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":27006,"source":{"system":"sec-edgar","filing":"0001662579-23-000021","document":"wf-form4_167528577737212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000021/wf-form4_167528577737212.xml","form_type":"4"}},{"id":2038254,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-02-01T21:09:52.000Z","date":"2023-01-30","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":31325,"source":{"system":"sec-edgar","filing":"0001662579-23-000021","document":"wf-form4_167528577737212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000166257923000021/wf-form4_167528577737212.xml","form_type":"4"}},{"id":2232252,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-06-14T20:45:52.000Z","date":"2022-05-26","kind":"tax_withholding","acquired":false,"shares":3675,"price":7.01,"value":25761.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":18825,"source":{"system":"sec-edgar","filing":"0001209191-22-036716","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000120919122036716/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-27"}},{"id":2233687,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T20:30:17.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023"}],"balance_after":25000,"derivative":{"exercise_price":12.31,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-22-006489","document":"form4-06132022_040606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000141588922006489/form4-06132022_040606.xml","form_type":"4"}},{"id":2252758,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2022-05-27T20:15:20.000Z","date":"2022-05-25","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":75000,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-032508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000120919122032508/doc4.xml","form_type":"4"}},{"id":2252757,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-05-27T20:15:20.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001209191-22-032508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000120919122032508/doc4.xml","form_type":"4"}},{"id":2298199,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-12T20:05:21.000Z","date":"2022-04-12","kind":"purchase","acquired":true,"shares":10000,"price":8.4,"value":84000.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-22-024130","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000120919122024130/doc4.xml","form_type":"4"}},{"id":2377311,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2022-02-23T21:30:46.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 72,500 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 72,500 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":87500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001209191-22-012216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000120919122012216/doc4.xml","form_type":"4"}},{"id":2678753,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-07T20:11:57.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2021 and is scheduled to vest in full on June 3, 2022."}],"balance_after":11538,"derivative":{"exercise_price":33.36,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001179110-21-006451","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000117911021006451/edgar.xml","form_type":"4"}},{"id":3012469,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-06T01:00:22.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":1691672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of this option shall vest and become exercisable on April 1, 2021, with the remainder vesting in 14 equal quarterly installments thereafter."}],"balance_after":1691672,"derivative":{"exercise_price":19,"expiration_date":"2030-09-30","underlying":"Common Stock","underlying_shares":1691672},"source":{"system":"sec-edgar","filing":"0000899243-20-027448","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000089924320027448/doc4.xml","form_type":"4"}},{"id":3111443,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-12T20:18:00.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021."}],"balance_after":11538,"derivative":{"exercise_price":27.49,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001179110-20-007273","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000117911020007273/edgar.xml","form_type":"4"}},{"id":3170122,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-04-24T20:06:36.000Z","date":"2020-04-22","kind":"exercise","acquired":false,"shares":5893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":11785,"derivative":{"underlying":"Common stock","underlying_shares":5893},"source":{"system":"sec-edgar","filing":"0001439222-20-000033","document":"wf-form4_158775877429935.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000033/wf-form4_158775877429935.xml","form_type":"4"}},{"id":3170121,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-04-24T20:06:36.000Z","date":"2020-04-22","kind":"tax_withholding","acquired":false,"shares":1927,"price":45.91,"value":88468.57,"ownership":{"direct":true},"balance_after":24272,"source":{"system":"sec-edgar","filing":"0001439222-20-000033","document":"wf-form4_158775877429935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000033/wf-form4_158775877429935.xml","form_type":"4"}},{"id":3170120,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-04-24T20:06:36.000Z","date":"2020-04-22","kind":"exercise","acquired":true,"shares":5893,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":26199,"source":{"system":"sec-edgar","filing":"0001439222-20-000033","document":"wf-form4_158775877429935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000033/wf-form4_158775877429935.xml","form_type":"4"}},{"id":3176463,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2020-04-15T20:26:42.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":5387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service.  The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service.  The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":10775,"derivative":{"underlying":"Common stock","underlying_shares":5387},"source":{"system":"sec-edgar","filing":"0001439222-20-000031","document":"wf-form4_158698238335139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000031/wf-form4_158698238335139.xml","form_type":"4"}},{"id":3176462,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-04-15T20:26:42.000Z","date":"2020-04-14","kind":"tax_withholding","acquired":false,"shares":1599,"price":40.64,"value":64983.36,"ownership":{"direct":true},"balance_after":20306,"source":{"system":"sec-edgar","filing":"0001439222-20-000031","document":"wf-form4_158698238335139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000031/wf-form4_158698238335139.xml","form_type":"4"}},{"id":3176461,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-04-15T20:26:42.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":5387,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":21905,"source":{"system":"sec-edgar","filing":"0001439222-20-000031","document":"wf-form4_158698238335139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000031/wf-form4_158698238335139.xml","form_type":"4"}},{"id":3249133,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-02-25T21:27:39.000Z","date":"2020-02-22","kind":"exercise","acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":6667,"derivative":{"underlying":"Common stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001439222-20-000024","document":"wf-form4_158266604156652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000024/wf-form4_158266604156652.xml","form_type":"4"}},{"id":3249132,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-02-25T21:27:39.000Z","date":"2020-02-24","kind":"tax_withholding","acquired":false,"shares":1056,"price":48.66,"value":51384.96,"ownership":{"direct":true},"balance_after":16518,"source":{"system":"sec-edgar","filing":"0001439222-20-000024","document":"wf-form4_158266604156652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000024/wf-form4_158266604156652.xml","form_type":"4"}},{"id":3249131,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-02-25T21:27:39.000Z","date":"2020-02-22","kind":"exercise","acquired":true,"shares":3333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":17574,"source":{"system":"sec-edgar","filing":"0001439222-20-000024","document":"wf-form4_158266604156652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000024/wf-form4_158266604156652.xml","form_type":"4"}},{"id":3262919,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-02-19T21:51:52.000Z","date":"2020-02-16","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2750,"derivative":{"underlying":"Common stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001439222-20-000016","document":"wf-form4_158214909552275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000016/wf-form4_158214909552275.xml","form_type":"4"}},{"id":3262918,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-02-19T21:51:52.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":45000,"derivative":{"exercise_price":51.51,"expiration_date":"2030-02-14","underlying":"Common stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001439222-20-000016","document":"wf-form4_158214909552275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000016/wf-form4_158214909552275.xml","form_type":"4"}},{"id":3262917,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-02-19T21:51:52.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":12000,"derivative":{"underlying":"Common stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001439222-20-000016","document":"wf-form4_158214909552275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000016/wf-form4_158214909552275.xml","form_type":"4"}},{"id":3262916,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-02-19T21:51:52.000Z","date":"2020-02-18","kind":"tax_withholding","acquired":false,"shares":886,"price":52.01,"value":46080.86,"ownership":{"direct":true},"balance_after":14241,"source":{"system":"sec-edgar","filing":"0001439222-20-000016","document":"wf-form4_158214909552275.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000016/wf-form4_158214909552275.xml","form_type":"4"}},{"id":3262915,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-02-19T21:51:52.000Z","date":"2020-02-16","kind":"exercise","acquired":true,"shares":2750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":15127,"source":{"system":"sec-edgar","filing":"0001439222-20-000016","document":"wf-form4_158214909552275.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000016/wf-form4_158214909552275.xml","form_type":"4"}},{"id":3489074,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T20:31:46.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020."}],"balance_after":11538,"derivative":{"exercise_price":21.74,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001179110-19-007685","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000117911019007685/edgar.xml","form_type":"4"}},{"id":3550028,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2019-04-24T21:38:04.000Z","date":"2019-04-22","kind":"grant","acquired":true,"shares":17678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":17678,"derivative":{"underlying":"Common stock","underlying_shares":17678},"source":{"system":"sec-edgar","filing":"0001209191-19-025785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119025785/doc4.xml","form_type":"4"}},{"id":3631960,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2019-02-26T21:27:17.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":10000,"derivative":{"underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-013536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119013536/doc4.xml","form_type":"4"}},{"id":3631959,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-02-26T21:27:17.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":58.86,"expiration_date":"2029-02-22","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-013536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119013536/doc4.xml","form_type":"4"}},{"id":3645711,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2019-02-20T21:05:28.000Z","date":"2019-02-16","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":5500,"derivative":{"underlying":"Common stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001209191-19-011491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011491/doc4.xml","form_type":"4"}},{"id":3645710,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2019-02-20T21:05:28.000Z","date":"2019-02-19","kind":"tax_withholding","acquired":false,"shares":821,"price":58.03,"value":47642.63,"ownership":{"direct":true},"balance_after":12374,"source":{"system":"sec-edgar","filing":"0001209191-19-011491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011491/doc4.xml","form_type":"4"}},{"id":3645709,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2019-02-20T21:05:28.000Z","date":"2019-02-16","kind":"exercise","acquired":true,"shares":2750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":13195,"source":{"system":"sec-edgar","filing":"0001209191-19-011491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011491/doc4.xml","form_type":"4"}},{"id":3689361,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share unit","published_at":"2019-01-23T21:22:56.000Z","date":"2019-01-20","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-004961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004961/doc4.xml","form_type":"4"}},{"id":3689360,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2019-01-23T21:22:56.000Z","date":"2019-01-22","kind":"tax_withholding","acquired":false,"shares":4555,"price":52.82,"value":240595.1,"ownership":{"direct":true},"balance_after":10445,"source":{"system":"sec-edgar","filing":"0001209191-19-004961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004961/doc4.xml","form_type":"4"}},{"id":3689359,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2019-01-23T21:22:56.000Z","date":"2019-01-20","kind":"exercise","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-19-004961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004961/doc4.xml","form_type":"4"}},{"id":3862196,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2018-07-24T20:34:39.000Z","date":"2018-07-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-043731","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118043731/doc4.xml","form_type":"4"}},{"id":3887911,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-19T20:04:22.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 15, 2018 and is scheduled to vest in full on June 15, 2019."}],"balance_after":11538,"derivative":{"exercise_price":37.5,"expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001179110-18-008769","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000117911018008769/edgar.xml","form_type":"4"}},{"id":4047488,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2018-02-20T21:03:50.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8250,"derivative":{"underlying":"Common stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001209191-18-011246","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118011246/doc4.xml","form_type":"4"}},{"id":4047487,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-02-20T21:03:50.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":33000,"derivative":{"exercise_price":77.7,"expiration_date":"2028-02-15","underlying":"Common stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001209191-18-011246","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118011246/doc4.xml","form_type":"4"}},{"id":4299437,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-31T20:56:42.000Z","date":"2017-05-30","kind":"grant","acquired":true,"shares":23076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2017 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on May 30, 2018 through May 30, 2020."}],"balance_after":23076,"derivative":{"exercise_price":13.75,"expiration_date":"2027-05-29","underlying":"Common Stock","underlying_shares":23076},"source":{"system":"sec-edgar","filing":"0001179110-17-008256","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586707/000117911017008256/edgar.xml","form_type":"4"}},{"id":4427621,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2017-02-23T21:07:40.000Z","date":"2017-02-21","kind":"grant","acquired":true,"shares":47600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":47600,"derivative":{"exercise_price":50.4,"expiration_date":"2027-02-20","underlying":"Common stock","underlying_shares":47600},"source":{"system":"sec-edgar","filing":"0001209191-17-013746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919117013746/doc4.xml","form_type":"4"}},{"id":4597910,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36225,"kind":"person","name":"Hirsch Andrew","position":1,"cik":"0001586707","reported_name":"Hirsch Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2016-09-21T20:16:15.000Z","date":"2016-09-20","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 20, 2016. The shares underlying this option vest as to 25% of the underlying shares on September 19, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":125000,"derivative":{"exercise_price":49.83,"expiration_date":"2026-09-19","underlying":"Common stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-16-142264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919116142264/doc4.xml","form_type":"4"}}]}